Valbiotis: Developing proprietary plant-derived biomolecules to prevent metabolic diseases. Initial pipeline includes 5+ products targeting prediabetes/T2D, NAFL/NASH, hypercholesterolemia, and obesity. Lead program VALEDIA®, targeting the unaddressed prediabetes market, is currently in a Ph 2a trial for the reduction of risk factors for developing Type 2 diabetes with results expected mid 2019. In a Ph1/2 trial in healthy volunteers, VALEDIA® demonstrated a good tolerance, and during a meal test an improvement of glucose tolerance (-13% Glucose Cmax), reduction in insulin secretion (-37% Insulin AUCnet), and consequently an improvement of insulin sensitivity (41%).
Sector/industry:
Biotech Company
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Cardiovascular, Diabetes, Metabolic Disorders
Industry
Biotechnology
Listing
Public
Market Cap
<100MM
Therapeutic Modalities
Microbiome
Website:
Address:
12F rue Paul Vatine
Périgny, 17180
France

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.